Corpus ID: 7367672

[Study on the safety and efficacy of sitafloxacin--results of the use-results survey].

  title={[Study on the safety and efficacy of sitafloxacin--results of the use-results survey].},
  author={Takuyuki Matsumoto and Kazuhiro Uchino and Hiroki Yamaguchi and Sanae Yoshida and Megumi Takahashi and Hiroko Kodama and Satoko Hamajima and Rie Yonemochi and Sachiko Fujita and Atsushi Takita and Naoki Yamanouchi and Tadamichi Suzuki and Tomoo Shiozawa and Fumie Yamaguchi},
  journal={The Japanese journal of antibiotics},
  volume={64 5},
Sitafloxacin (STFX, Gracevit 50 mg, fine granules 10%), a new quinolone antibacterial agent, was approved in January 2008, and the use-results survey was performed for 2 years from December 2008 to November 2010. In total, 3558 case cards were collected from 287 medical institutions and 3331 cases were subjected to a safety evaluation and 3225 were subjected to an efficacy evaluation. Incidence of adverse drug reactions (ADRs) was 4.44% (148/3331 cases). Major ADRs were diarrhea (55 cases) and… Expand
Clinical dose findings of sitafloxacin treatment: pharmacokinetic–pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections
  • S. Kohno, Y. Niki, +7 authors Y. Tanigawara
  • Medicine
  • Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • 2013
For cases in which a sufficiently high Cpeak is necessary to ensure the susceptibility of the pathogens to the drug, 100 mg sitafloxacin once daily should be administered. Expand
Bacterial Infections in the Elderly Patient: Focus on Sitafloxacin
Oral sitafloxacin is a promising therapeutic agent which merits further investigation in randomized clinical trials of elderly patients and covers broad spectrum of bacteria as compared to carbapenems, whereas in the Caucasians its use is currently limited due to the potential for ultraviolet A phototoxicity. Expand
A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia
Sitafloxacin 100 mg qd or 100’mg bid for 7–10 days is not inferior to moxifloxACin 400  mg qd for 7-10’days in clinical efficacy for adult CAP patients. Expand
New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae
ABSTRACT The emergence of high-level resistance to ceftriaxone is giving rise to serious concern about absence of effective treatment options to cure gonococcal infections. Increasing the dosageExpand
A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants
Adapting an adenylate kinase (AK)-based cell death reporter assay to identify members of a Food and Drug Administration (FDA)-approved drug library that display bactericidal activity against S. aureus SCV demonstrated the ability to use the AK assay to screen small-molecule libraries for SCV bactericidal agents and highlight the therapeutic potential of sitafloxacin to be repurposed to treat chronic S.Aureus infections. Expand
DC-159a Shows Inhibitory Activity against DNA Gyrases of Mycobacterium leprae
In vitro assays indicated that DC-159a and sitafloxacin are more effective against wild type and mutant M. leprae DNA gyrases than moxiflOxacin, suggesting that these antibacterial drugs can be good candidates that may supersede current fluoroquinolone remedies. Expand
Studies on DNA gyrase of quinolone-resistant Mycobacterium leprae [an abstract of dissertation and a summary of dissertation review]. 論文内容の要旨
Title Studies on DNA gyrase of quinolone-resistant Mycobacterium leprae [an abstract of dissertation and a summary of dissertation review] Author(s) 山口, 智之 Citation 北海道大学. 博士(獣医学) 甲第12621号 Issue DateExpand
Development of hemiacetal esterified levofloxacin to prevent chelation with metal‐containing drugs
To avoid the chelate formation between levofloxacin (LVFX) and aluminium hydroxide in gastrointestinal tract, an ethoxycarbonyl 1‐ethyl hemiacetal ester of levofloxacin (LVFX‐EHE) was synthesised asExpand